34 research outputs found
Minimally invasive stereotactic puncture and thrombolysis therapy improves long-term outcome after acute intracerebral hemorrhage
The purpose of this study was to judge the clinical value of minimally invasive stereotactic puncture and thrombolysis therapy (MISPTT) for acute intracerebral hemorrhage (ICH). A randomized control clinical trial was undertaken. According to the enrollment criteria, 122 acute ICH cases were analyzed, of which 64 cases received MISPTT (MISPTT group, MG) and 58 cases received conventional craniotomy (CC group, CG). The Glasgow coma scale (GCS) scores, postoperative complications (PC), and rebleeding incidences were compared. Moreover, 1 year postoperation, the long-term outcomes of patients with regard to hematoma volume (HV) <50 mL and HV ≥50 mL were judged, respectively, by the Glasgow outcome scale (GOS), Barthel index (BI), modified Rankin Scale (mRS), and case fatality (CF). MG patients showed obvious amelioration in GCS score compared with that of CG patients. The total incidence of PC in MG decreased compared with that of CG. The incidences of rebleeding in MG and CG were 9.4 and 17.2%, respectively (P = 0.243). There were no obvious differences between the CFs of MG and CG (17.2 and 25.9%, respectively, P = 0.199). The GOS, BI, and mRS representing long-term outcome for both HV <50 mL and HV ≥50 mL in MG were ameliorated significantly greater than that in CG patients (all P < 0.05). These data suggest that there are advantages with MISPTT not only in trauma and safety, but the MISPTT group had fewer complications and a trend toward improved short-term and long-term outcomes
Economic evaluation of seizures associated with solitary cysticercus granuloma
Background: Patients with solitary cysticercus granuloma (SCG) develop
acute symptomatic seizures because of the inflammatory response of the
brain and the seizures are self-limiting. Thus seizure disorder
associated with SCG provides a good model to study the total cost of
illness (COI). Materials and Methods: COI of new-onset seizures
associated with SCG was studied in 59 consecutive patients registered
at the epilepsy clinic. Direct treatment-related costs and indirect
costs, man-days lost and wages lost were evaluated. The relative cost
was calculated as the percentage of per capita gross national product
(GNP) at current prices for the year 1997-1998. Results: The total
COI, for treating seizure disorder associated with SCG per the period
of CT resolution of the lesion per patient was INR 7273.7 (US 943.16) and he/she would be spending 50.9% of per capita GNP The
direct cost per patient was INR 5916 (US132.2, 40%
of per capita GNP). The extra expenditure on albendazole and steroid
was INR 213.72 (US 30.42) and it accounted for 9% of per capita GNP. The
one-time expenditure at present costs (adjusted for inflation) to the
nation to treat all the prevalence cases is to the tune of INR 1.184
billion (US 2.605 million) and 0.0037% of GNP